Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...

In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...

I, however, just wanted to get my firewood off the porch, where it was overly sheltered for anything but fully dried wood, ...

Joplin doesn’t chase trends. No AI noise, no bloated features. It quietly does the job of being a reliable second brain, and ...

Now that we’re a few weeks removed from the official launch of the Magic: The Gathering Final Fantasy Universes Beyond […] ...